Neptune's Martin backs biotech to outperform mid caps

Neptune manager Mark Martin is backing niche medical companies to outperform the UK's mid-cap sector this year.

Martin, who runs the Neptune UK Mid Cap fund, has a large position in biotech firm BTG. Although small and mid caps have had an exceptionally strong run over the last year, driving Martin's fund to the top of the IMA UK Mid Cap sector over the last year, the manager predicts there is further to go in some parts of the index, and highlighted biotech as one area he expects to outpeform. Martin said BTG is one of the few pharmaceuticals companies to have a successful pipeline of "potentially revolutionary" drugs. "It is inventing and discovering new drugs, and this is something large pha...